Skip to main content
Premium Trial:

Request an Annual Quote

Decode Q1 Revenue Falls, Net Loss Narrows

NEW YORK (GenomeWeb News) April 28 - Iceland's Decode Genetics today reported revenue of $10.3 million and a net loss of $12 million for its first quarter ending March 31.

 

In the same quarter last year, the company reported revenue of $11.8 million and a net loss of $13 million.

 

The company said it has accrued $19 million in deferred research revenue, an increase of $6 million over the same quarter in 2003, reflecting cash received under the company's alliance with Merck. This, and other deferred revenue, the company said, will be recognized over future reporting periods.

 

Decode spent $15.4 million in research in development in its first quarter, compared to $19.7 million for the same quarter in 2003.

 

The company had $97 million in cash and cash equivalents on hand as of March 31.

 

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more